目的 探讨蒲地蓝消炎口服液联合注射用炎琥宁治疗小儿病毒性肺炎的临床疗效。方法 选择2015年2月-2017年2月襄阳市中心医院收治的110例小儿病毒性肺炎为研究对象，依据抽签法将110例患儿随机分为对照组和治疗组，每组各55例。对照组患儿静脉滴注注射用炎琥宁，10 mg/kg加入5%葡萄糖溶液250 mL中，1次/d；治疗组在对照组的基础上口服蒲地蓝消炎口服液，10 mL/次，3次/d。两组患儿均连续治疗10 d。观察两组的临床疗效，比较两组的临床症状改善情况、肺功能、血清炎症因子水平。结果 治疗后，对照组和治疗组的总有效率分别为74.55%、90.91%，两组比较差异有统计学意义（P<0.05）。治疗后，治疗组患儿退热时间、咽痛消失时间、啰音消失时间、血象恢复时间、止咳时间均显著短于对照组，两组比较差异有统计学意义（P<0.05）。治疗后，两组患儿最高呼气流速（PEF）、用力肺活量（FVC）、1秒钟用力呼气容积（FEV1）和1秒用力呼气容积占用力肺活量百分比（FEV1/FVC）均显著升高，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗后治疗组患儿肺功能指标均显著高于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患儿血清超敏C反应蛋白（hs-CRP）、白细胞介素-6（IL-6）水平均显著低于对照组，同组治疗前后比较差异具有统计学意义（P<0.05）；且治疗后治疗组患儿血清炎症因子水平均显著低于对照组，两组比较差异有统计学意义（P<0.05）。结论 蒲地蓝消炎口服液联合注射用炎琥宁治疗小儿病毒性肺炎临床效果较好，能缓解患儿的临床症状，改善肺功能，降低炎症反应，具有一定的临床推广应用价值。

Objective To investigate the clinical efficacy of Pudilan Xiaoyan Oral Liquid combined with Potassium Sodium Pehydroandroandrographolide Succinate for injection in treatment of viral pneumonia in children. Methods Children (110 cases) with viral pneumonia in Xiangyang Central Hospital from February 2015 to February 2017 were randomly divided into control and treatment groups, and each group had 55 cases. Children in the control group were iv administered with Potassium Sodium Pehydroandroandrographolide Succinate for injection, 10 mg/kg added into 5% glucose solution 250 mL, once daily. Patients in the treatment group were po administered with Pudilan Xiaoyan Oral Liquid on the basis of the control group, 10 mL/time, three times daily. Patients in two groups were treated for 10 d. After treatment, the clinical efficacies were evaluated, and the improvement of clinical symptoms, pulmonary function, and the serum levels of inflammatory factors in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 74.55% and 90.91%, respectively, and there was difference between two groups (P<0.05). After treatment, antipyretic time, pharyngeal pain time, rales time, blood picture recovery time, and cough relief time in the treatment group were significantly shorter than those in the control group, and there was difference between two groups (P<0.05). After treatment, PEF, FVC, FEV1, and FEV1/FVC in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the pulmonary function indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, CRP and IL-6 levels in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the serum levels of inflammatory factors indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). Conclusion Pudilan Xiaoyan Oral Liquid combined with Potassium Sodium Pehydroandroandrographolide Succinate for injection has clinical curative effect in treatment of viral pneumonia in children, can alleviate the clinical symptoms, improve the lung function, and reduce the inflammatory reaction, which has a certain clinical application value.